Clinical Trial Update: BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing biweekly bevacizumab plus trifluridine/tipiracil for metastatic colorectal cancer. The study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• trifluridine/tipiracil (trifluridine/tipiracil)

Snippet

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: NOT_YET_RECRUITING